Last reviewed · How we verify
NCT05172388
Indoor Air Filtration and Young Adults Health Study
NA trial testing Air purifier in Cardiopulmonary Diseases in 81 participants. Completed in 30 April 2022.
30 April 2022
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 81 |
| Start date | 29 December 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Air purifier
Conditions studied
- Cardiopulmonary Diseases — all drugs for Cardiopulmonary Diseases →
Sponsor
Peking University
Who can join
Adults 18 to 28, any sex, with Cardiopulmonary Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the cardiopulmonary health effects of indoor air purification and other indoor environmental conditions among young healthy college students in Beijing, China.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Indoor Environment and Health Effects: Protocol of an Exploratory Panel Study among Young Adults in China (China IEHE Study).
Liu S, Wang W, Zhao Y, Li L, et al · · 2025 · cited 3× · PMID 39839245 · DOI 10.1021/envhealth.4c00051
Verify or expand the search:
- PubMed search for NCT05172388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Air purifier
Trials testing the same drug.
- NCT06534385 — The Clean Air Study: HEPA Purifiers to Improve Indoor Air Quality and Health in Rural Alaska Homes · NA · recruiting
- NCT06691568 — Effectiveness of an Air Purifier on Asthmatic and Cat-allergic Subjects in the ALYATEC Environmental Exposure Chamber · NA · completed
- NCT04252235 — Home Air Purification for Eosinophilic COPD · NA · completed
- NCT03319056 — Indoor Air and Children Health Study · NA · completed
- NCT03301402 — Air Purifier to Improve Endothelial Function and Carotid Intima Thickness · NA · completed
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05172388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 13 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing